The article “Standing Guard” was published on the PDA Letter website Sept. 26. This response addresses what we consider misleading conclusions within the article. As manufacturers of recombinant Factor C (rFC) endotoxin detection assays—known as the bioMérieux ENDONEXT™ family of products, we are committed to providing an accurate portrayal of the emerging limulus amebocyte lysate (LAL) replacement reagent rFC.